Its architect's daughter has cystic fibrosis—and benefits from a "miracle drug" backed by an agency he's attacking.

Drugmakers — major beneficiaries of NIH-backed university research — have been largely silence on the Trump administration's cuts to agency research payments.

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex ...

Vertex Pharmaceuticals Inc. ( ($VRTX) ) has released its Q4 earnings. Here is a breakdown of the information Vertex Pharmaceuticals Inc. presented ...

Vertex Pharmaceuticals Inc. will soon lose a member of its leadership team that helped the company achieve major revenue ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...

Did you see this? Nearly 1 in 10 Americans have asthma. Here's what causes it.

Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...

Two sizable companies and a handful of small Asian issuers were listed in the US this past week. Read more here.